Business Insider27d
Jonathan Wolleben’s Positive Outlook on Structure Therapeutics, Inc. Driven by Unique Small Molecule Amylin Agonist and Promising Obesity Pipeline
Jonathan Wolleben’s rating is based on the significant potential he sees in Structure Therapeutics, Inc., particularly due to its position as a leader in small molecule amylin agonists.
Hosted on MSN2mon
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
Beyond GSBR-1290, Structure is progressing with the development of an orally administered small molecule amylin receptor agonist for obesity treatment. The company aims to finalize a development ...
Yahoo Finance1mon
Iktos and Cube Biotech Announce Launch of Small Molecule AI Drug Discovery Collaboration
Existing GLP-1 receptor agonist therapies like semaglutide or the peptide Amylin analogue Pramlintide have limited impact due to high costs, accessibility, and undesirable side effects. Orally ...
FierceBiotech1d
Ascletis' swift surge into obesity continues with competitive oral GLP-1 data
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
Pharmabiz29d
Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity
ASC30 oral tablet demonstrated superior PK properties (including a longer t1/2 and higher AUC) to other small molecule oral GLP-1 receptor (GLP-1R) agonists in development, suggesting ASC30 oral ...